Manoalide, a natural inhibitor of PLA2, has been identified as a potential EGFR-TKI sensitizer for KRAS-mutated and osimertinib-resistant lung cancer organoid by inhibiting the KRAS-ERK signaling pathway (93). The gene discussed is KRAS; the disease is lung carcinoma.